A new trading day began on Monday, with Neumora Therapeutics Inc (NASDAQ: NMRA) stock price up 4.83% from the previous day of trading, before settling in for the closing price of $11.17. NMRA’s price has ranged from $8.33 to $21.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 59.37%. With a float of $54.91 million, this company’s outstanding shares have now reached $158.83 million.
Considering the fact that the conglomerate employs 124 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Neumora Therapeutics Inc (NMRA) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Neumora Therapeutics Inc is 65.69%, while institutional ownership is 27.78%. The most recent insider transaction that took place on Oct 18 ’24, was worth 239,319. In this transaction Director of this company sold 14,049 shares at a rate of $17.03, taking the stock ownership to the 20,100 shares. Before that another transaction happened on Oct 17 ’24, when Company’s Director sold 7,739 for $17.01, making the entire transaction worth $131,643. This insider now owns 20,100 shares in total.
Neumora Therapeutics Inc (NMRA) Recent Fiscal highlights
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -1.14 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.37 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 59.37% per share during the next fiscal year.
Neumora Therapeutics Inc (NASDAQ: NMRA) Trading Performance Indicators
Here are Neumora Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 17.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.74, a number that is poised to hit -0.39 in the next quarter and is forecasted to reach -1.55 in one year’s time.
Technical Analysis of Neumora Therapeutics Inc (NMRA)
Compared to the last year’s volume of 0.71 million, its volume of 1.08 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 10.06%. Additionally, its Average True Range was 0.93.
During the past 100 days, Neumora Therapeutics Inc’s (NMRA) raw stochastic average was set at 38.16%, which indicates a significant increase from 13.71% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 80.30% in the past 14 days, which was higher than the 62.77% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.92, while its 200-day Moving Average is $12.67. Nevertheless, the first resistance level for the watch stands at $12.16 in the near term. At $12.60, the stock is likely to face the second major resistance level. The third major resistance level sits at $13.26. If the price goes on to break the first support level at $11.05, it is likely to go to the next support level at $10.39. Now, if the price goes above the second support level, the third support stands at $9.95.
Neumora Therapeutics Inc (NASDAQ: NMRA) Key Stats
With a market capitalization of 1.83 billion, the company has a total of 160,028K Shares Outstanding. Currently, annual sales are 0 K while annual income is -235,930 K. The company’s previous quarter sales were 0 K while its latest quarter income was -58,700 K.
